

Resource Summary Report

Generated by [dkNET](#) on Aug 2, 2026

APC/Cyanine7 anti-human CD3

RRID:AB_314054

Type: Antibody

Proper Citation

BioLegend Cat# 300318, RRID:AB_314054

Antibody Information

URL: http://antibodyregistry.org/AB_314054

Proper Citation: BioLegend Cat# 300318, RRID:AB_314054

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC/Cyanine7 anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone HIT3a

Antibody ID: AB_314054

Vendor: BioLegend

Catalog Number: 300318

Alternative Catalog Numbers: 300317

Record Creation Time: 20250819T231641+0000

Record Last Update: 20250820T045041+0000

Ratings and Alerts

No rating or validation information has been found for APC/Cyanine7 anti-human CD3.

No alerts have been found for APC/Cyanine7 anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhong L, et al. (2025) Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. *Cell*, 188(4), 1119.

Chen L, et al. (2025) CD94/NKG2A-Qa-1b axis as a key modulator of vaccine responsiveness in aging populations. *Cell reports*, 44(11), 116514.

Benamar M, et al. (2025) Notch3 destabilizes regulatory T cells to drive autoimmune neuroinflammation in multiple sclerosis. *Immunity*, 58(11), 2753.

Lee YJ, et al. (2025) Tumor-specific but immunosuppressive CD39+CD8+ T cells exhibit double-faceted roles in clear cell renal cell carcinoma. *Cell reports. Medicine*, 102360.

Kinoshita S, et al. (2024) Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer. *Cancer research communications*, 4(3), 723.

Ansari A, et al. (2024) T-B coculture assay for functional analysis of antigen-specific memory CD4+ T cells. *STAR protocols*, 5(2), 103119.

Bukhari S, et al. (2023) Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. *Cell reports. Medicine*, 4(1), 100868.

Cao W, et al. (2023) TRIB2 safeguards naive T cell homeostasis during aging. *Cell reports*, 42(3), 112195.

Abhiraman GC, et al. (2023) A structural blueprint for interleukin-21 signal modulation. *Cell reports*, 42(6), 112657.

Cheng Y, et al. (2023) High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. *Cell reports. Medicine*, 4(10), 101214.

Herzig MC, et al. (2023) Short-term assays for mesenchymal stromal cell immunosuppression of T-lymphocytes. *Frontiers in immunology*, 14, 1225047.

Shemesh A, et al. (2022) Diminished cell proliferation promotes natural killer cell adaptive-like phenotype by limiting Fc γ RI α expression. *The Journal of experimental medicine*, 219(11).

Ansari A, et al. (2022) An efficient immunoassay for the B cell help function of SARS-CoV-2-specific memory CD4 $^{+}$ T cells. *Cell reports methods*, 2(6), 100224.

Lopez P, et al. (2022) T cell migration potentiates HIV infection by enhancing viral fusion and integration. *Cell reports*, 38(8), 110406.

Clayton KL, et al. (2021) HIV-infected macrophages resist efficient NK cell-mediated killing while preserving inflammatory cytokine responses. *Cell host & microbe*, 29(3), 435.

Hearnden R, et al. (2021) Isolation of stromal vascular fraction cell suspensions from mouse and human adipose tissues for downstream applications. *STAR protocols*, 2(2), 100422.

Kreutmair S, et al. (2021) Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia. *Immunity*, 54(7), 1578.

Wang F, et al. (2021) A basophil-neuronal axis promotes itch. *Cell*, 184(2), 422.

Basar R, et al. (2021) Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. *Cell reports*, 36(3), 109432.

Beatson RE, et al. (2021) TGF- β 1 potentiates V α 9V β 2 T cell adoptive immunotherapy of cancer. *Cell reports. Medicine*, 2(12), 100473.